City of Hope to Present New Research at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, Highlighting Promising Data on Stem Cell Transplantation, Blood Cancers and Supportive Care Oncology Interventions

World-renowned physicians and researchers from City of Hope^®, one of the largest cancer research and treatment organizations in the United States, will present new findings and offer expert perspectives on leading-edge cancer research and treatment development at the ASCO Annual Meeting 2024, which will take place in Chicago from May 31 to June 4.

In total, City of Hope experts will present at 64 sessions, including oral abstracts, rapid oral abstracts, clinical science symposiums and education sessions.

ORAL AND RAPID ORAL ABSTRACT SESSIONS

• "Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator's choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC)"
  Session LBA 3510 presenting Monday, June 3, from 1:21 to 1:27 p.m. CT
  Session title: Gastrointestinal Cancer?Colorectal and Anal
  Presenter: Marwan G. Fakih, M.D., City of Hope professor, Department of Medical Oncology & Therapeutics Research
  

• "Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation"
  Session 6503 presenting on Friday, May 31, from 3:45 to 3:57 p.m. CT
  Session title: Hematologic Malignancies?Leukemia, Myelodysplastic Syndromes, and Allotransplant
  Presenter: Monzr M. Al Malki, M.D., City of Hope associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
  

• "Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study"
  Session 7008 presenting on Saturday, June 1, from 5:24 to 5:36 p.m. CT
  Session title: Hematologic Malignancies?Lymphoma and Chronic Lymphocytic Leukemia
  Presenter: Tycel Phillips, M.D., City of Hope associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
  

• "Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2? inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma"
  Session 4513 presenting Saturday, June 1, from 8:30 to 8:36 a.m. CT
  Session title: Genitourinary Cancer?Kidney and Bladder
  Presenter: Sumanta Kumar Pal, M.D., FASCO, City of Hope professor, Department of Medical Oncology & Therapeutics Research

CLINICAL SCIENCE SYMPOSIUMS

• "Geriatric assessment-directed supportive care intervention (GAIN-S)-implementation via telehealth in a lower-resourced community"
  Session 1510 presenting Saturday, June 1, from 1:39 to 1:51 p.m. CT
  Session title: Patient-Centered Care for Older Adults With Cancer
  Presenter: Tanyanika Phillips, M.D., M.P.H., City of Hope assistant clinical professor, Department of Medical Oncology & Therapeutics Research
  Senior author: William Dale, M.D., Ph.D., FASCO, City of Hope professor, Department of Supportive Care Medicine
  

• "Quality of life for older patients with metastatic cancer in Brazil: A telehealth-based geriatric assessment and supportive care intervention (GAIN-S)"
  Session 1514 presenting Sunday, June 2, from 11:54 a.m. to 12:06 p.m. CT
  Presenter: Cristiane Decat Bergerot, Ph.D.
  Senior author: William Dale, M.D., Ph.D., FASCO, City of Hope professor, Department of Supportive Care Medicine

POSTER ABSTRACT SESSION

• "A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling"*
  Session 1038 on Sunday, June 2, from 9 a.m. to noon CT
  Session Title: Breast Cancer?Metastatic
  Presenter: Alexis LeVee, M.D., City of Hope Hematology & Medical Oncology Chief Fellow
  * Conquer Cancer, the ASCO Foundation, awarded LeVee a 2024 ASCO Annual Meeting Merit Award, which supports students and trainees who are first authors on abstracts selected for presentation.

At the meeting, ASCO will recognize researchers who have reshaped cancer care. City of Hope's William Dale, M.D., Ph.D., FASCO, is the recipient of this year's B.J. Kennedy Geriatric Oncology Award, which honors geriatric oncologists who have demonstrated outstanding leadership and achievement in the field of geriatric oncology. Dale is the first non-oncologist recipient in the history of the award. Of note, Dale is first author of ASCO's recent cancer and aging guideline update.

• Online on-demand award lecture on Friday, May 31, from 1 to 1:45 p.m. CT
  Presenter: William Dale, the George Tsai Family Chair in Geriatric Oncology and vice chair for academic affairs in the Department of Supportive Care Medicine at City of Hope

EDUCATION SESSIONS

• "Evidence Evaluating Cannabis' Efficacy Across the Cancer Care Continuum"
  Monday, June 3, from 8:30 to 8:45 a.m. CT
  Session title: Evidence-Based Integrative Oncology: Guideline Insights for Comprehensive Care
  Presenter: Richard T. Lee, M.D., FASCO, City of Hope clinical professor, Supportive and Integrative Medicine Program; Cherng Family Director's Chair for the Center for Integrative Oncology
  

• "Tissue-Based Molecular Testing and the Role of Artificial Intelligence"
  Monday, June 3, from 10 to 10:15 a.m. CT
  Session title: Should I Order the Test? Expanding the Array of Emerging Diagnostics in Breast Cancer
  Presenter: Daniel Schmolze, M.D., City of Hope associate clinical professor, Department of Pathology
  

• "What Is Variant Histology Renal Cell Cancer and What Are the Available Treatment Options?"
  Monday, June 3, from 3:15 to 3:30 p.m. CT
  Session title: Managing Variant Histologies in Urothelial and Renal Cell Cancers
  Presenter: Sumanta Kumar Pal, M.D., FASCO, City of Hope professor, Department of Medical Oncology & Therapeutics Research

About City of Hope

City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope's growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope's affiliated group of organizations includes Translational Genomics Research Institute and AccessHope^TM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.